Results 161 to 170 of about 4,976,429 (317)

Other title: Two Thousand Thirteen Kansas Behavioral Risk Factor Surveillance System

open access: yes, 2015
application/pdf; Report Preparation: Jeanie Santaularia [and] Ginger Park. Report Supervision: Ghazala Perveen.; "Partial funding for the 2013 Behavioral Risk Factor Survey was provided by cooperative agreement 5U58SO0000008-03 from the Centers for ...
Kansas. Bureau of Health Promotion.
core  

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

open access: yesMolecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy   +10 more
wiley   +1 more source

Other title: Two Thousand Fourteen Kansas Behavioral Risk Factor Surveillance System

open access: yes, 2016
application/pdf; Report Preparation: Ericka Welsh [and] Ghazala Perveen.; "Partial funding for the 2014 Kansas Behavioral Risk Factor Surveillance System (BRFSS) was provided by cooperative agreement 6NU58DP006025-01-01 from the Centers for Disease ...
Kansas. Bureau of Health Promotion.
core  

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

open access: yesMolecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel   +12 more
wiley   +1 more source

Bullying : health, well-being and risk behaviours

open access: yes, 2011
The HBSC Study in Scotland is funded by NHS Health ...
Alexander, L, Mellor, A, Currie, Candace
core  

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy